Home › Funds › MONTANOVA CAPITAL, LLC › ARQT

MONTANOVA CAPITAL, LLC position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

MONTANOVA CAPITAL, LLC reported holding 12,437,000 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$326.1M, representing 5.96% of its reported portfolio and ranking #3 among its reported holdings. MONTANOVA CAPITAL, LLC has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)12.44M sh
Reported value held$326.10M
Portfolio Weight5.96%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MONTANOVA CAPITAL, LLC's ARQT position evolved

MONTANOVA CAPITAL, LLC first disclosed a stake in ARQT in Q3 2023 at 1,135,227 shares (US$6.0M). The position peaked in Q4 2025 at 11,964,000 shares, worth US$347.4M. Across 12 filings, MONTANOVA CAPITAL, LLC increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 12,437,000 shares valued at US$326.1M — an increase of 110,000 shares quarter over quarter.. Notable position changes include a 646% increase in Q4 2023 (shares rose 207% over the following quarter), a 27% increase in Q2 2024 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.14M $6.03M New
Q4 2023 8.47M $27.37M Add
Q1 2024 7.88M $78.06M Reduce
Q2 2024 10.00M $93.04M Add
Q3 2024 10.72M $99.71M Add
Q4 2024 11.40M $158.79M Add
Q1 2025 11.42M $178.66M Hold
Q2 2025 11.54M $161.73M Add
Q3 2025 10.48M $197.51M Reduce
Q4 2025 11.96M $347.43M Add
Q1 2026 12.33M $290.42M Add
Q2 2026 12.44M $326.10M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M), ORBIMED ADVISORS LLC (US$53.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has MONTANOVA CAPITAL, LLC held ARQT?

MONTANOVA CAPITAL, LLC has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is MONTANOVA CAPITAL, LLC's current position in ARQT?

As of Q2 2026, MONTANOVA CAPITAL, LLC holds 12.44M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $326.10M, representing 5.96% of its reported portfolio and ranking #3.

Has MONTANOVA CAPITAL, LLC been buying or selling ARQT?

In the latest 13F filing (Q2 2026), MONTANOVA CAPITAL, LLC increased its position in ARQT. The position peaked in Q4 2025 at 11.96M shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include Frazier Life Sciences Management, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.